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Abstract 
Tumours in rodent and human colon share many histological and genetic features. To know if rodent models of colon 
carcinogenesis are good predictors of chemopreventive efficacy in humans, we made a meta-analysis of aspirin, beta-
carotene, calcium, and wheat bran studies. Controlled intervention studies of adenoma recurrence in human volunteers were 
compared with chemoprevention studies of carcinogen-induced tumours in rats, and of polyps in Min (Apc(+/-)) mice: 6714 
volunteers, 3911 rats and 458 mice were included in the meta-analyses. Difference between models was small since most 
global relative risks were between 0.76 and 1.00. A closer look showed that carcinogen-induced rat studies matched human trials 
for aspirin, calcium, carotene, and were compatible for wheat bran. Min mice results were compatible with human results for 
aspirin, but discordant for calcium and wheat bran (no carotene study). These few results suggest that rodent models roughly 
predict effect in humans, but the prediction is not accurate for all agents. Based on three cases only, the carcinogen-induced rat 
model seems better than the Min mouse model. However, rodent studies are useful to screen potential chemopreventive 
agents, and to study mechanisms of carcinogenesis and chemoprevention. 
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1. Introduction 
Some 100,000 rodents have been sacrificed on the 
chemoprevention altar. This number was estimated from the 
colon cancer chemoprevention database : 
http://www.inra.fr/reseau-nacre/sci-memb/corpet/indexan.html  
The estimate also includes liver, mammary, oesophagus, 
pancreas prostate, and skin cancer studies. Were these 
sacrifices useful? Were the time, efforts, and money needed 
to raise rodents, and to try to prevent their tumours of any 
use? The answer may seem obvious, since rodents and 
humans share many biological functions, and rodents are 
valuable for toxicity tests. Rodent studies are needed in the 
chemoprevention area, because epidemiological studies do 
not lead to firm conclusions: confusing factors cannot be 
fully eliminated. Thus, the hypotheses generated by 
epidemiology must be tested in controlled experiments, 
ideally in humans (1). But this is very long and costly, and it 
could jeopardize volunteers' health. Thus, animal trials 
should precede human trials. For instance, animal studies 
should have been completed before beta-carotene 
administration to smokers (2, 3). It is not, however, so 
obvious that animal chemoprevention studies are useful (4). 
Major differences between rodents and humans in lifespan, 
body weight, intestinal morphology (e.g., caecum),  gut 
microflora, way of eating (e.g., meals, chewing, 
coprophagia), and gene regulation may change the outcome 
of dietary interventions. Also, the profound differences in 
efficacy seen, even in different studies using one model, 
cast doubt on their relevance for clinical studies (5). The 
question thus needs to be scrutinized. 
How good are rodent models of carcinogenesis in 
predicting chemopreventive efficacy in humans? From a 
theoretical viewpoint, how similar, or dissimilar, are 
rodent and human tumours? From an empirical viewpoint, 
are the chemopreventive effects of agents tested in rodents 
and humans consistent or discrepant? This review focuses 
on colorectal cancer prevention only, and goes through 
four steps: (i) Comparison of the mechanisms of colon 
carcinogenesis in humans and in animal models. (ii) 
Review of human intervention studies aimed at preventing 
colorectal tumours. (iii) Meta-analysis of animal 
intervention studies (4). The meta-analysis was restricted 
to aspirin, beta-carotene, calcium and wheat bran, the only 
agents tested in several human trials. (iv) The efficacy of 
chemopreventive agents in animals and in humans was 
then compared.  
2. Comparison of the mechanisms of colon 
carcinogenesis in humans and in animal models 
Let us look first at colon carcinogenesis in humans, then in 
rodent models. Vogelstein model relates the histological 
progression from normal tissue to cancer with the 
sequential accumulation of mutations (6, 7). Most human 
adenocarcinoma would evolve from aberrant crypt foci 
(ACF) and adenoma. This model has been progressively 
enriched, and several interdependent pathways are now 
accepted, based on the analysis of sporadic tumours and of 
two inherited syndromes: the familial adenomatous 
polyposis (FAP) and hereditary nonpolyposis colorectal 
cancers (HNPCC). Germline mutation of the Apc gene 
determines the FAP syndrome. Most colorectal cancers are 
sporadic (90%), but they share with FAP tumours the 
same early Apc mutation in 50 to 80% of cases. In most 
sporadic colon cancers, like in FAP, a consequence of Apc
gene mutation is b-catenin accumulation. Indeed APC 
protein forms a complex with b-catenin, axin, and 
glycogen synthase-3 kinase (GSK3). Axin promotes -
catenin phosphorylation that mediates its degradation in 
the proteasome (8). In normal cell, this is regulated by the 
Wingless/Wnt signaling pathway. But Apc mutation 
prevents the formation of the complex, and b-catenin level 
rises in the cytoplasm. The stabilized -catenin associates 
with transcription factor Tcf4. b-catenin-Tcf4 translocates 
into the nucleus, and induces constitutive activation of c-
myc, cyclin D1 and c-jun (9). The disruption of the Wnt/b-
catenin/Tcf pathway is thus a major event in most colon 
cancers.  Chromosomal instability (CIN), a common 
feature of 8/10 colorectal cancers (10), goes with Apc
mutation. Truncated APC protein may loose its ability to 
connect chromosomes to microtubules. Defective 
chromosome segregation, and CIN, would thus result from 
mutated Apc. Furthermore, in the tumours where Apc is 
intact, the b-catenin gene is mutated, and stabilized -
catenin translocates into the nucleus and triggers c-myc, 
cyclin D1 and c-jun. In the multiple steps process from 
normal cell to carcinoma, other genes are mutated or 
deleted. The oncogene K-ras is mutated in the early stage 
of colon carcinogenesis, while tumour suppressor genes 
(DCC and p53) are involved in later stages (11). The 
process is also associated with over-expression of iNOS and 
COX-2, with resulting increase in nitric oxide and 
prostaglandin E2 levels. HNPCC syndrome is not due to 
Apc mutation but to a mutation in a mismatch repair 
(MMR) gene: several MMR genes are implicated as first 
event (Mlh1, Msh2, Msh6, Pms1, Pms2). Mutation rate is 
100–1000-fold greater in MMR-deficient cells than in 
normal cells. This is evidenced by microsatellite instability 
(MSI), which participates to the hypermutable phenotype 
(12). Most microsatellites are found in noncoding DNA, 
but some mutations due to MSI modify genes involved in 
later stages of carcinogenesis, e.g., transforming growth 
factor- receptor II and insulin like growth factor II 
receptor. Besides mutations, human tumours have a 
general DNA hypomethylation, but the aberrant 
hypermethylation of promoter CpG islands leads to 
transcriptional silencing of key growth-controlling genes 
and contributes to cancer progression (13). 
Do tumours in animal models, i.e. carcinogen-initiated rats 
and mutated mice, share the genetic events and the 
histological features of human cancers? The use of 
carcinogens has been necessary because laboratory rodents 
have extremely low spontaneous rates of colon cancer. Most 
published studies were done in rats injected with 
dimethylhydrazine (DMH) or its metabolite, azoxymethane 
(AOM). AOM-induced tumours in rats share many 
histopathologic characteristics with human tumours, and 
similarly go through ACF, adenoma (often polyps) and 
carcinoma. They, like human tumours, often bear K-ras
mutation (30-60%), but, unlike human tumours, they seldom 
have a mutated Apc (8%), and never a p53 mutation. 
However, like Apc mutated human tumours, rat tumours 
accumulate b-catenin in the nucleus. This is due to Ctnnb1
mutation, which produces a b-catenin resistant to 
degradation (14). Alternatively, a mutation in the GSK3b 
phosphorylation motif of the b-catenin gene can reduce b-
catenin degradation (15). Heterocyclic amines, e.g., 2-
amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), are 
also used to induce tumours in rats or mice. PhIP induces 
Apc (15%) and -catenin mutations (50%) in the colon of 
rats (16). The direct acting nitrosamine methylnitrosourea 
(MNU) has been used in few studies. In contrast with 
DMH-, AOM- and PhIP-induced tumours, no Apc or b-
catenin mutations were detected in MNU-induced 
tumours. Thus, Wnt/-catenin/Tcf pathway plays a major 
role in human tumours and in carcinogen-induced rat 
tumours. Like in humans, COX-2 and iNOS are over-
expressed in these tumours. However, these rodent 
carcinogens are not found in human diet (except PhIP), 
and use of large doses of a carcinogen is not comparable to 
the human situation. Although the carcinogen-induced 
tumours look similar to human tumours, we do not really 
know if they develop like spontaneous tumours. Perhaps 
the protection (or the promotion) depends on the tumour 
initiator.  
A mutant mouse, Min, was found with multiple intestinal 
neoplasia in 1990 (17). It was shown to have a germline 
inactivation of one Apc gene, similar to that in patients with 
FAP, and in many sporadic cancers. This promising animal 
model mimics the rapid development of adenomatous 
polyps that affect FAP patients. The Apc protein deficiency 
in Min mice results from a premature translational stop 
codon at amino acid 850. Other mice have also been 
genetically modified on Apc with truncations in positions 
580, 716, 1309, or 1638. Like in humans, different 
mutations lead to different phenotypes and Wnt/b-
catenin/Tcf pathway plays an important role in mutant 
mice carcinogenesis. For instance, Min mice have ten times 
more polyps than Apc1638, but six times fewer than Apc716 
mutant mice (18). In addition, COX-2 and iNOS play an 
important role in Min mice carcinogenesis, like in humans: 
knockout Min mice with deleted COX-2 or iNOS gene(s) 
develop fewer adenomas than "wild-type" Min mice (19, 
20). Like in humans, methylation plays a role in Min mice 
carcinogenesis, since a reduction in DNA 
methyltransferase activity suppresses polyp formation 
(21). K-ras and p53 mutations are not detected in Min mice 
tumours, in contrast with human tumours. Besides Apc
mutant mice, mice with Msh2 or Mlh1 gene mutations were 
obtained, but their phenotype does not make them a clear 
model for HNPCC patients (22). However, Msh2-deficient 
mice develop small intestinal tumours and sebaceous 
gland tumors analogous to Msh2-mutated patients (Muir–
Torre syndrome). Like human HNPCC, Msh2-/- and 
Mlh1-/- mouse cells display high mutation frequencies and 
MSI (23).  
Table 1: Experimental colon tumour prevention in Man. Randomized double-blinded placebo-controlled published intervention 
studies are ranked by potency to prevent polyp recurrence, and grouped by agent.  
Agent  or Diet Reference   Relative Risk   
(95% confidence 
interval) 
No. of 
treated  
patients
Length, 
 months
Daily  dose Colon  
endpoint 
Primary   
endpoint 
Selenium Clark 96 0.42 (0.18-0.95)  653 54 200 µg Cancer incid. Skin cancer
vitC,vitE,Bcar,Se,Zn Hercberg 04 0.71 (0.39-1.31) 2520 90 176 mg Cancer incid. All cancers
Celecoxib Steinbach 00 0.72 polyp/patient 30FAP 6 800 mg Polyp no. 
Sulindac Giardiello 02 0.78 (0.4-1.5) 21FAP 48 300 mg Polyp no.  
Calcium Baron 99 0.85 (0.74-0.98) 464 18 1.2 g Polyp recur.  
Calcium Bonithon 00 0.66 (0.38-1.17) 176 36 2 g Polyp recur.  
Calcium +vit. Mix Hofstad 98 0.71 (0.5-1.0) 42 36 1.6 g Polyp recur. Polyp growth
Aspirin Baron 03 0.81 (0.69-0.96) 377 33 81 mg Polyp recur.  
Aspirin Baron 03 0.96 (0.81-1.13) 372 33 325 mg Polyp recur.  
Aspirin Benamouzig 03 0.61 (0.37-0.99) 60 12 300 mg Polyp recur.  
Aspirin Benamouzig 03 0.85 (0.57-1.26) 66 12 160 mg Polyp recur.  
Aspirin Gann 93 0.86 (0.68-1.10) 11035 60 162 mg Polyp incid. Heart attack
Aspirin Sandler 03 0.65 (0.46-0.91) 317 31 325 mg Polyp recur.  
Ursodeoxycholic acid Alberts 05 0.88 (0.73-1.05) 661 32 75 0 mg Polyp recur.  
Wheat bran Alberts 00 0.88 (0.7-1.1) 719 35 +11 g Polyp recur.  
Wheat bran MacLennan 95 1.2 (0.8-2.0) 150 48 +25 g Polyp recur.  
Wheat bran McKeown 94 1.2 (0.6-2.2) 99 24 +15 g Polyp recur.  
Low fat  MacLennan 95 0.9 (0.6-1.5) 151 48 -7% Polyp recur.  
Low fat  McKeown 94 1.2 (0.6-2.2) 99 24 -9% Polyp recur.  
Low fat  Schatzkin 00 1.00 (0.90-1.12) 958 36 -10% Polyp recur.  
Beta-carotene Greenberg 94 1.01 (0.85-1.20) 359 48 25 mg Polyp recur.  
Beta-carotene MacLennan 95 1.5 (0.9-2.5) 156 48 20 mg Polyp recur.  
Beta-carotene Hennekens 96 1 NS 11035 144 25 mg All cancers Heart attack
Beta-carotene Malila 99 0.98 (0.71-1.35) 7761 78 20 mg Polyp incid. Lung cancer 
Fruits & vegetables Schatzkin 00 1.00 (0.90-1.12) 958 36 +2serv Polyp recur.  
Vit. C + vit. E Greenberg 94 1.08 (0.91-1.29) 380 48 1+0.4 g Polyp recur.  
Vit. C + vit. E McKeown 88 0.86 (0.51-1.45) 70 24 0.4+0.4 g Polyp recur.  
Vit. E Malila 99 1.66 (1.19-2.32) 7768 78 50 mg Polyp incid. Lung cancer 
Psyllium  Bonithon 00 1.67 (1.01-2.76) 198 36 3.5 g Polyp recur.   
The (Apc(+/-)) mice are promising models of human 
colorectal cancer (24). However, a major drawback is that 
the tumours occur predominantly in the small intestine, not 
the colon. In addition, ACF and adenocarcinomas are not or 
seldom observed in this model. However, two new mutant 
mice may avoid these drawbacks. Germline targeted 
deletion of Apc exon 14 leads to severe colon polyposis: 5-
15 polyps develop in these mice colo-rectum, vs. 0.4-4 in 
other Apc mutants (25). Other mice, with a N-terminal 
truncated -catenin (A33Ncat), develop few spontaneous 
ACF in the colon, like human and rat models (26).  
Taken together, rodent models grow tumours that share 
many histological and genetic features with humans. The 
major differences between rodents and humans are the 
small bowel location of tumours in Min mice (vs. human 
colon), and the mutation of beta-catenin gene in AOM-
injected rats (vs. human Apc mutations). These 
conclusions render it pertinent to examine studies of 
intestinal tumour chemoprevention in humans, and to 
compare them with results obtained in rodent models. 
3. Experimental chemoprevention of intestinal tumours 
in humans
Randomized, placebo-controlled trials directed at preventing 
the recurrence of colonic adenomatous polyps in human 
volunteers are considered the gold standard for 
chemoprevention studies though they do have limitations. 
The major one is that the study end-point is not cancer 
incidence but adenoma recurrence. Other limitations are the 
short length of the intervention compared with the duration 
of the disease, the possible lack of compliance with the 
protocol, and the inclusion of subjects that differ from the 
general population (3). Two agents, calcium (27-29) and  
aspirin (30-32), consistently reduced polyp recurrence in 
several intervention studies (Table 1). The estimated 
"weighted mean RRs" for calcium and aspirin were 0.79 
and 0.85 respectively (weighted by study size). A recently 
published meta-analysis finds an RR= 0.80 (CI: 0.68, 
0.93) for calcium supplement (33), which is close to the 
value estimated here, 0.79. Interventions with high wheat 
bran and/or low fat diet, beta-carotene or vitamin C and E 
had no effect at all on polyp recurrence (34-39). The 
"weighted 
Table 2: Meta-analysis of chemoprevention studies in carcinogen-initiated rats, dealing with aspirin, beta-carotene, calcium 
and wheat bran protection. Relative risks (RRs) calculated with Random Model, except underlined values, calculated by 
Chi-square test on 2x2 tables. Data subsets shown in italics (full data and figures on http://corpet.net/min)  
Treatment 2x2 Table : No. of Rats RR 95% C.I. p Value 
With tumour  Total 
Aspirin treated rats 313 559 0.84 0.75-0.95 0.006
No aspirin controls 167 252 0.86 0.77-0.96 0.007 
Aspirin during initiation only   0.68 0.42-1.16 0.13 
Aspirin "both" periods   0.80 0.67-0.95 0.012 
Aspirin post-initiation only   0.92 0.79-1.08 0.32 
    
Beta-carotene treated rats 54 95 0.76 0.61-0.93 0.005
No beta-carotene controls 82 109 0.72 0.47-1.08 0.11 
    
High calcium treated rats 548 984 0.91 0.84-0.99 0.03
Low calcium controls 456 748 0.92 0.85-1.00 0.06 
Calcium  in High Fat diets   0.93 0.86-1.02 0.11 
Calcium in Low Fat diets   0.92 0.77-1.11 0.38 
Calcium lactate   0.72 0.55-0.94 0.02 
Ca phosph., carbon., gluconate   0.99 0.95-1.04 0.74 
    
Wheat bran treated rats 307 595 0.83 0.75-0.91 0.0002
No wheat bran controls 355 569 0.87 0.77-0.97 0.015 
Wheat bran in High Fat diets   0.79 0.66-0.93 0.006 
Wheat bran in Low Fat diets   0.91 0.78-1.07 0.26 
 mean RRs" were estimated to be 0.96, 1.00, 1.00 and 1.04 
respectively. Table 1 shows the effect of other 
interventions: mixtures, complex dietary changes, or once 
only tested agents. We chose to focus this meta-analysis 
on agents fulfilling two criteria: (i) well-defined agent, (ii) 
several concordant human trials. Accordingly, aspirin, 
beta-carotene, calcium, and wheat bran effect in rodents 
were further examined. 
4. Chemoprevention in animal models of intestinal 
carcinogenesis. 
According to the provocative article by Pound et al. (4), 
systematic reviews should become routine to ensure the 
best use of existing animal data, and improve the estimates 
of effect from animal experiments. We thus made a 
systematic review of aspirin, beta-carotene, calcium, and 
wheat bran dietary chemoprevention studies in two animal 
models of colorectal cancer: carcinogen-initiated rats (and 
mice), and mice mutated on the Apc gene (Min mice 
mainly).  
4.1. Methods. 
The meta-analysis of carcinogen-injected rats was done as 
follows: we searched articles on Medline/PubMed database 
and in "references" sections (cut-off date, January 2005). 
Some papers were not included: not in English, poor 
protocol, missing or aberrant data (list given on 
http://corpet.net/min). Studies were far from homogeneity 
(all Q Cochran's p<0.01), which disqualified "Fixed Effects" 
model (40). "Random Effects" model was used to calculate 
common RR, 95% confidence intervals (95%CI) and p 
values (40), which are shown in Table 2. Funnel plots were 
drawn to detect publication bias, which were tested by rank 
test (40). However, the Random model calculation needed 
to duplicate some control data, because many studies use a 
single control group for several treated groups. Each control 
rat was thus included several times in the table, which 
should not be. We thus added a second approach, by 
pooling data. It is not recommended as a rule because it 
gives too little weight to studies with low baseline levels of 
adenomas. Raw number of tumour-bearing rats, and of 
tumour-free rats, in control and treated groups, were 
included in a table, and summed up as if all rats had been 
treated in a single study (each control rat was included only 
once). The 2x2 contingency table with all rats (shown on 
Table 2) was then analysed with Chi-square statistics 
without Yates correction, and 95%CI were calculated and 
shown in Table 2. Pooling of data from all studies was 
chosen, including rats and mice, initiated by various 
carcinogens, and treated with various doses. We reasoned 
that when a human population is treated with a 
chemopreventive agent, people are exposed to various 
carcinogens, and have different genetic backgrounds and 
different diets. We thus had no a priori reason to exclude 
any rodent protocol.  
The meta-analysis of Min mice intestinal polyp studies was 
done as follows: Global Effect Size and p value were first 
calculated with "Random Effects" model (40), and given in 
the "Results" section. However a second approach was also 
used, because "Effect Size" cannot be compared with RR. 
We thus chose to use ratios instead of differences. Number 
of adenomas per mouse in treated group was divided by 
corresponding value in control group and multiplied by 100, 
for each study. The mean of these percentages was 
compared with the hypothetical 100% value (H0 hypothesis) 
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Table 3 Summary of dietary prevention of colorectal tumours in rats, mice and humans: Efficacy of agents to reduce polyp 
recurrence in humans, tumour incidence in rats, and polyp number in mice. 
Agent or Diet
Humans, 
mean polyp 
recurrence
Carcinogen-initiated rats, 
colon tumour incidence
Min mice, 
Polyp number,  
(small bowel)
RR c N e RR (95%CI)c Rats 
/men 
N e PR (95%CI)i Mice 
/men 
N e
Aspirin a 0.85 S d 4 0.86 (0.77-0.96) OK h 8 0.94 (0.73-1.15) j  ±OK 7
Beta-carotene 1.00 NS d 4 0.72 (0.47-1.08)g OK 4 No study  0 
Calcium 0.79 S 3 0.92 (0.85-1.00) OK 13 1.09-1.21 NO 1 
Wheat bran 0.96 NS 3 0.87 (0.77-0.97) ±OK 12 0.64 (0.54-0.84) NO 5 
Selenium  b 0.42 S 1 0.50 S OK 7 0.60 S OK 3 
Celecoxib 0.72 S (1) f 0.20 S ±OK 2 0.60 S OK 4 
Sulindac 0.78 NS (1) f 0.60 S ±OK 8 0.50 S ±OK 15 
Low fat  1.00 NS 3 0.80 NS OK 10 0.70 S NO 1 
Fruits & veg.  1.00 NS 1 1.00 NS OK 8 1.20 NS OK 4 
Vit. C + vit. E 1.04 NS 2 1.00 NS OK 11   0 
Psyllium 1.67 S 1 0.36 S  NO 1   0 
Notes to table 3. 
a- Top-panel data come from this meta-analysis (Table 2), full data and figures on http://corpet.net/min 
b- Bottom-panel data (in italics) from ref. (18): no true meta-analysis approach. 
c- RR: relative risk of polyp recurrence (humans) or of colon tumour incidence (rats). 
d- S, significant. NS, not significant.  
e- Number of articles included in the meta-analysis.  
f- Small scale study of polyp number reduction in FAP patients. 
g- Not significant by Random model analysis, but significant by chi-square analysis (see Table 2).  
h- OK: rodent data match human data; ±OK: no direct match but human RR within 95%CI; NO: rodent data differ from human data. 
i- PR: polyp ratio, number of intestinal polyps in treated mice divided by number in control mice. 
Not significant by Student's t test, but significant by Random model analysis: Effect Size= -0.29, 95%CI= -0.55; -0.03 
sample Student t test. Also, a weighted mean was calculated, 
taking in account the number of mice per study. Full rats and 
mice data and figures are shown on website 
http://corpet.net/min, and data are summarized here in 
Table 2 (rats) and Fig. 1 (Min mice). 
4.2. Results 
4.2.1. Aspirin effect in carcinogen-injected rats.  
The meta-analysis of eight publications (41-48) including 
811 rats showed that aspirin reduces colon tumour incidence 
in rats: RR= 0.84 (p=0.006), with similar RR with Random 
model analysis (0.86, p=0.007). Analysis of subsets where 
aspirin was given only before or after the initiation is 
compatible with the hypothesis that the protection is higher 
when aspirin treatment is given during initiation (Table 2). 
4.2.2. Aspirin effect in mutated mice.  
Seven articles including 232 mice with an Apc mutation 
provide data on aspirin (49-55). Number of intestinal 
adenomas in treated mice was 94% of number in controls 
(Fig.1, p= 0.59). Effect Size analysed by Random Model 
was -0.29 (p=0.03). This small reduction of small intestinal 
polyps was thus significant or not, according to model. 
Furthermore, aspirin treatment did not reduce the number of 
colonic polyps (Fig.1-B). According to Perkins et al. (55) 
aspirin prevents the early phase of carcinogenesis, and 
would be active only before birth and until weaning. Data 
subsets were analysed to test this hypothesis. Mean number 
of polyps in the two early-treated groups of mice were 74 
and 80% of controls (Fig. 1, open circles), vs. 102% in mice 
only treated after weaning. This is compatible with the 
hypothesis or early protection. 
- 
Figure 1: Effect of interventions on number of tumours in 
Apc mutated mice, expressed as percent of control (full 
data on http://corpet.net/min). A: Small intestine. B: Large 
intestine. Open circles: pre-birth administration (aspirin), 
or "Western diet" (data not included into calcium meta-
analysis) 
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4.2.3. Beta-carotene effect in carcinogen-injected rodents. 
The meta-analysis of four studies (56-59) including 204 rats 
and mice showed that beta-carotene reduces colon tumour 
incidence in rodents: RR= 0.76 (p=0.005). However, this 
RR was not significant using Random model analysis (0.72, 
p=0.11, Table 2). No study of beta-carotene in Min mice 
was found. 
4.2.4. Calcium effect in carcinogen-injected rats.  
The meta-analysis of 17 publications (44, 47, 60-75) 
including 1732 rats showed that calcium reduces colon 
tumour incidence in rats: RR= 0.91 (p=0.03), with similar 
RR with Random model (0.92, p=0.06). The hypothesis that 
calcium specifically reduces high-fat diet promotion was 
tested by analysing separately studies with high fat (>20% 
fat, w/w) and low fat diets (< 6%), but both subsets yielded 
similar RRs and p values (Table 2). Also, we tested the 
hypothesis that some calcium salts were more protective 
than others. This was indeed the case: calcium lactate was 
protective in rats (RR=0.7, p=0.02, Table 2), but phosphate, 
carbonate and gluconate afforded no protection (RR=1). 
4.2.5. Calcium effect in mutated mice.  
Small intestinal polyp yield increases by +9 and +21% when 
dietary calcium doubles (ref. (76), 79 mice). Calcium did 
not reduce the number of colonic polyps either (Fig. 1-B). In 
contrast, mice fed the high-calcium AIN76 diet had fewer 
polyps than mice fed the low-calcium Western diet designed 
by Newmark (77-79). This polyp reduction to 37% of 
control value (weighted mean, p<0.001) cannot however be 
attributed to calcium alone, since diets also differed for 
phosphate, fat, and vitamin D content (Fig 1, open circles).  
4.2.6. Wheat bran effect in carcinogen-injected rats.  
A significant protection by wheat bran is shown in two out 
of twelve publications (80-91). Meta-analysis, including 
1164 rats, showed that wheat bran reduces colon tumour 
incidence in rats (RR= 0.83, p=0.0002), with similar RR in 
Random model analysis (0.87, p=0.015). The hypothesis 
that wheat bran specifically prevents fat promotion was 
tested by analysing separately studies with high fat and low 
fat diets. Wheat bran indeed protected rats given a high-fat 
diet (RR= 0.79, p=0.006), but not rats given a low-fat diet 
(Table 2). 
4.2.7. Wheat bran effect in mutated mice.  
The eight studies (92-96) gathering 147 Min mice showed a 
protective effect of wheat bran (Fig 1-A). Number of small 
intestinal polyps in wheat bran-fed mice was 69% of control 
number (weighted mean, 66%, p=0.001), and effect size was 
-0.74 by Random model analysis (p<0.001). Bran also 
marginally decreased colonic tumours (p=0.07, Fig.1-B). 
5. Comparison of intestinal chemoprevention in 
humans and in animal models. 
Table 3 shows that aspirin, beta-carotene, calcium, and 
wheat bran effect in men, rats and mice led to RRs 
comprised between 0.72 and 1.00 (and PRs between 0.64 
and 1.15): no promotion and no strong protection were 
observed (Fig. 2). The effects of four agents in three models 
were thus similar. However, Table 3 significances and 
95%CIs suggest that: (i) Aspirin protected men and rats, but 
Figure 2: Chemoprevention in humans and rodents (data 
from Table 3). Colon polyp recurrence RR in humans vs. 
tumour RR in chemically-induced rats (panel RAT vs. 
MAN), or vs. Polyp Ratio in Apc mutated mice (panel 
MOUSE vs. MAN). Black points: meta-analysis data. 
Grey points: tentative values from ref (18). Italics: RR 
significance discordant in humans and rodents.  
not Min mice (but human RR was within mice PR 95%CI), 
(ii) Beta-carotene did not protect rats or men (no published 
Min mice study), (iii) Calcium protected men and rats, 
although effect in men was stronger than in rats. In a single 
study, Min mice were not protected (76), and (iv) Wheat 
bran protected mice and rats, but not men (but human RR 
was within rat 95%CI). Carcinogen-induced rat studies 
matched human trials for aspirin, calcium, carotene, and 
were compatible for wheat bran. Min mice results were 
compatible with human results for aspirin, but discordant for 
calcium and wheat bran (no carotene study). However, the 
size of these discrepancies was small and may not be 
meaningful. Bottom of Table 3 reports rodent data from a 
previous review (18). These results should be considered 
with caution, because the true meta-analysis approach was 
not undertaken in rodents, and because the effect in humans 
relied on single studies (except low fat). The effect of most 
of the diets or agents was consistent across the various 
models except one striking discrepancy: psyllium afforded 
strong protection in one rat study, and significant promotion 
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in one human study. However, the first published study of 
psyllium (not reported here) showed a strong promotion in 
DMH-initiated rats (97). The previous review concluded 
there was a reasonable agreement between the results of the 
animal studies and the more limited clinical studies (18). 
The present meta-analysis somewhat challenges this 
conclusion, because the prediction is not accurate for all 
agents, and carcinogen-induced rats model seems better than 
Min mice model.  
6. Discussion 
This meta-analysis of experimental studies suggests that the 
effects of aspirin, beta-carotene, calcium, and wheat bran 
were not strikingly different in humans, rats and mice (Fig. 
2). However, the hypothesis that chemopreventive agents 
produce the same effect in animals and in humans has 
hitherto not been tested. Robust analysis would require 
solid data on more than four agents, and with more 
contrasted RRs (e.g., below 0.5 and above 1.0). Table 3 
already suggests that selenium, celecoxib, and sulindac 
effect in rodents could match the effect in volunteers. 
Rodent models thus roughly predict effect in humans. A 
closer look at table 3 shows that carcinogen-induced rat 
studies matched human trials for aspirin, calcium, carotene, 
and were compatible for wheat bran. Min mice results were 
compatible with human results for aspirin, but discordant for 
wheat bran and calcium (single calcium article, and no 
carotene study). Table 3 also suggests discordances for 
psyllium in rats, and low fat diet in mice. Thus the rodent 
models do not predict accurately the outcome of 
intervention studies in humans for all agents, and Min mice 
do not appear to be superior to carcinogen-induced rats. The 
following four considerations may explain the apparent 
discrepancies between rodents and humans: 
(i) Some agents may not afford the same protection in 
rodents and in humans (e.g., wheat bran). This means that 
rodent models would not be reliable predictors to detect 
chemopreventive agents. 
(ii) Differences in study design could preclude any precise 
quantitative comparison between rodents and humans. 
Notably, genetic, diet, environment and treatment are fully 
controlled in rodent studies, not in human trials. 
 (iii) Publication bias could distort rodent results. Bias is 
probably much higher for rodent than for human studies. In 
contrast with human trials, null or negative rodent studies 
are less likely to be published than positive ones. This bends 
the mean of rodent results toward protection. For instance, 
several scientists have indicated to the authors that in their 
opinion their manuscripts were declined because the results 
contradicted a currently accepted dogma (e.g., calcium is 
protective). To illustrate this point, the funnel plot of aspirin 
data in rats showed a significant publication bias (plot 
shown on htt://corpet.net/min, p=0.0007). Calcium and 
wheat bran data show no clear evidence for bias. However, 
to reduce publication bias, there should be an ethical 
obligation to post all unpublished results on an internet 
archive.  
(iv) Lastly, the meta-analysis itself might be inaccurate. We 
may have missed important studies, or the pooling of studies 
with different protocols was perhaps not a good choice. 
Because RRs were close to 1.00, changing the calculation 
method could change the significance (see notes g and j to 
Table 3). However, these choices were made a priori, and 
there was no intention to bias the conclusion, which indeed 
contradicts the authors starting opinion. 
Could the artificial use of a potent carcinogen, or of a 
germline mutation, be the cause of the poor predictivity of 
rodent models? In Newmark's model, normal mice were fed 
a "Western diet", which contains high fat and phosphate, 
and low calcium, vitamin D, fibres, folic acid and vitamin 
B12. Eighteen months later, spontaneous colon tumours 
were observed in five mice out of  twelve (98). Could this 
model be the ultimate one to predict tumour prevention in 
humans, as advocated by Bruce (99)? This notion is a 
distinct possibility, because, like in humans, the addition of 
calcium (and vitamin D) to the diet reduced tumour 
incidence in mice (98). 
Animal studies may "predict" what happens in humans. 
Here are two examples from our laboratory. The first 
example is the serendipitous discovery that polyethylene 
glycol (PEG) is a potent chemopreventive agent in rats 
(100). Four years later, a population study showed that 
humans taking PEG-based laxatives have only half the risk 
of developing colorectal adenoma compared to non-users
(101). Another example is beef meat promotion of 
carcinogenesis in rats. According to epidemiological studies 
(102) consumption of beef has been suggested to increase 
colon cancer risk in humans.  Tumour promotion by beef 
may be mediated by myoglobin haem iron, and is fully 
inhibited by a high calcium diet (103). These data prompted 
the authors to ask epidemiologists to re-evaluate cohort 
results. Such evaluation showed that high calcium intake 
was associated with a stronger protection in those eating 
high levels of red meat than in those eating less than 25 g 
red meat/day (A. Flood, unpublished observation).
Well known agents such as aspirin might perhaps not have 
been the best ones to be subjected to this analysis, since they 
seem to afford only modest protection in rats and in 
volunteers. One may surmise that the most potent agents 
discovered in animal studies might afford consistent 
protection when tested in volunteers. Rodent models suggest 
that PEG, hesperidin, Bowman-Birk protease inhibitor, 
sphingomyelin, physical exercise, EGF-receptor-kinase 
inhibitor, (+)-catechin, resveratrol, fish oil, curcumin, 
caffeic acid phenetyl-ester and S-methyl-methane-
thiosulfonate might well be efficacious preventive agents 
that have not yet been tested in humans (1, 18). However, 
the safety of giving a daily pill to thousand of healthy people 
for many years needs to be carefully evaluated prior to a 
trial (99), in order to avoid the negative results associated 
with beta-carotene and specific COX2 inhibitors (104).  
In conclusion, how useful are the animal models? Do we 
have to agree with the letter sent by R. Greek and J. Greek 
to the Brit. Med. J. on 5 February, 2001? (Full text on 
http://bmj.bmjjournals.com/cgi/eletters/322/7281/248#124
07) "Animals can only be proven to be “models” 
empirically. That is to say, we must know what happens in 
humans first, then study animals to see if a particular 
animal replicates the human condition… But this is a 
catch-22. We can only know which animal mimics humans 
after we know what happens in humans. But after we know 
how humans respond there is no need to use animals. This 
gives us no new knowledge, is obviously not predictive, 
and thus obviates the need for animals."  
Although one cannot disagree completely with the 
underlying sentiment expressed in this letter and has to 
admit that the empirical approach is necessary, rodent 
studies remain undoubtedly useful for the following 
reasons: 
(i) To screen for potential chemopreventive agents, and to 
eliminate agents that have no effect or promote tumour 
growth. In Table 3, all the agents which decrease polyp 
recurrence in volunteers also decrease tumour incidence in 
rats. Agents with no effect in rats produced no effect in 
humans. However in this demonstration tumour promoters 
have been omitted: no agent which promotes tumours in 
rodents has ever been tested in humans. It may therefore be 
prudent to use rodent models as screening tools: agents 
which turn out to be inefficacious or tumour-promoting in 
rodents should not be tested in humans. An appropriate role 
for animals in cancer chemoprevention is thus the “initial 
screen”. Such screens may well discover as yet unknown 
potent chemopreventive agents like PEG (1, 100). 
(ii) To allow the study of mechanisms. Invasive 
procedures and use of toxic compounds pose less ethical 
problems in rodents than in humans. Less time and money 
are required to test a hypothesis in rodents than in humans. 
Mice with modified or knocked out genes can be 
constructed to directly test some hypotheses. However one 
has to bear in mind that the relevance for humans of 
mechanisms found in rodents is doubtful if not validated in 
humans. For instance, attractive mechanisms explain how 
wheat bran prevents carcinogenesis in rats (105), but 
human trials show that wheat bran does not prevent 
colorectal adenoma. 
(iii) To help identify new biomarkers and novel target 
genes. These can subsequently be detected in humans. For 
instance, ACF were first identified in the rat colon 
exposed to carcinogens (106), and they have subsequently 
been identified in the human colon. The numbers of ACFs 
increase with increasing risk of colon cancer, and they 
represent an attractive target for intervention (107). Also, 
novel gene targets were identified in human tumours on 
the basis of evidence collected from transcriptional 
profiles in Min mice (108).  
Finally, this meta-analysis suggests that rodent models 
roughly agree with human data, but do not predict 
accurately the efficacy of all chemopreventive agents in 
humans. Human beings will however not be able to find 
new ways to prevent cancer without the help of animal 
models. 
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